Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial

IMPORTANCE Obesity is a major health problem in China; more pharmacotherapy choices for long-term weight management are needed. OBJECTIVE To evaluate the efficacy and safety of once-weekly subcutaneous ribupatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, for weight loss in adults in China with overweight or obesity without diabetes. DESIGN, SETTING, AND PARTICIPANTS This multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial was conducted at 55 sites in China. From May to June 2024, adults without diabetes who had a body mass index of 28 or greater or 24 or greater with at least 1 weight-related comorbidity were enrolled, with final follow-up on June 20, 2025. INTERVENTIONS Participants were randomized to receive once-weekly subcutaneous ribupatide (target doses of 2 mg, 4 mg, or 6 mg) or matching placebo for 48 weeks, with dose escalation for up to 20 weeks and concomitant lifestyle intervention. MAIN OUTCOMES AND MEASURES The primary outcome was change in body weight from baseline to week 48, including percent change in body weight and the percentage of participants achieving at least 5% body weight reduction, analyzed under the treatment policy estimand. RESULTS Among 567 randomized participants (309 [54.5%] female; mean [SD] age was 34.4 [8.4] years, body weight was 93.0 [17.3] kg, and body mass index was 33.3 [4.5]), 514 (90.7%) completed the 48-week treatment period. Least-squares mean percentage changes in body weight at week 48 were −10.7%, −16.4%, and −17.7% with ribupatide 2, 4, and 6 mg, respectively, vs −1.4% with placebo. At week 48, the placebo-adjusted differences in percentage change in body weight were −9.3 (95% CI, −11.4 to −7.3) percentage points with ribupatide 2 mg, −15.0 (95% CI, −17.1 to −12.9) percentage points with ribupatide 4 mg, and −16.3 (95% CI, −18.4 to −14.2) percentage points with ribupatide 6 mg ( P < .001 for all). For at least 5% body weight reduction at week 48, the multiply imputed response rates were 68.1% (95% CI, 59.9% to 75.3%) for ribupatide 2 mg (97 of 142), 88.0% (95% CI, 81.3% to 92.6%) for ribupatide 4 mg (124 of 141), 85.7% (95% CI, 78.6% to 90.7%) with ribupatide 6 mg (121 of 141), and 16.0% (95% CI, 10.8% to 23.1%) with placebo (23 of 143). Placebo-adjusted differences for ribupatide 2, 4, and 6 mg were 52.0 (95% CI, 42.2 to 61.9), 72.0 (95% CI, 63.7 to 80.2), and 69.7 (95% CI, 61.1 to 78.3) percentage points, respectively (all P < .001). The most frequent treatment-emergent adverse events with ribupatide were gastrointestinal events, occurring in 47.9%, 58.2%, and 63.1% of participants receiving ribupatide 2 mg, 4 mg, and 6 mg, respectively, compared with 23.1% receiving placebo; most were mild to moderate in severity and few participants (0.7%) permanently discontinued study treatment because of adverse events. CONCLUSIONS AND RELEVANCE Among adults in China with overweight or obesity without diabetes, once-weekly subcutaneous ribupatide resulted in significantly greater weight loss at 48 weeks. Gastrointestinal adverse events were the most frequent tolerability findings. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT06396429

Authors

Institutions

Publication Details

Journal
JAMA
Published
2026-11-15
DOI
https://doi.org/10.1001/jama.2026.24796
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial

Qi Wang, L Wang, Zongyou Cheng, Hongye Su et al.
JAMA
Pharmacology and Obesity Treatment
article

Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial

Qi Wang, L Wang, Zongyou Cheng, Hongye Su, Lei Zhang, Yi Xu, Jinyang Wang, Dan Zhu, YIKE WANG, MEIFANG ZENG, Yue ZUO, Minzhi Lv, Zhifeng Cheng, Chao Meng, Ying Chen, Guiping Li, Lin Zhao, Qifu Li, Xiaoying Li, Lianwei Wang, Wenhua Wei, Yuan Hui, Shu Li, Shumei Zhong, Hanqing Cai, Hong Chen, Junfeng Han
article en

Abstract

IMPORTANCE Obesity is a major health problem in China; more pharmacotherapy choices for long-term weight management are needed. OBJECTIVE To evaluate the efficacy and safety of once-weekly subcutaneous ribupatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, for weight loss in adults in China with overweight or obesity without diabetes. DESIGN, SETTING, AND PARTICIPANTS This multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial was conducted at 55 sites in China. From May to June 2024, adults without diabetes who had a body mass index of 28 or greater or 24 or greater with at least 1 weight-related comorbidity were enrolled, with final follow-up on June 20, 2025. INTERVENTIONS Participants were randomized to receive once-weekly subcutaneous ribupatide (target doses of 2 mg, 4 mg, or 6 mg) or matching placebo for 48 weeks, with dose escalation for up to 20 weeks and concomitant lifestyle intervention. MAIN OUTCOMES AND MEASURES The primary outcome was change in body weight from baseline to week 48, including percent change in body weight and the percentage of participants achieving at least 5% body weight reduction, analyzed under the treatment policy estimand. RESULTS Among 567 randomized participants (309 [54.5%] female; mean [SD] age was 34.4 [8.4] years, body weight was 93.0 [17.3] kg, and body mass index was 33.3 [4.5]), 514 (90.7%) completed the 48-week treatment period. Least-squares mean percentage changes in body weight at week 48 were −10.7%, −16.4%, and −17.7% with ribupatide 2, 4, and 6 mg, respectively, vs −1.4% with placebo. At week 48, the placebo-adjusted differences in percentage change in body weight were −9.3 (95% CI, −11.4 to −7.3) percentage points with ribupatide 2 mg, −15.0 (95% CI, −17.1 to −12.9) percentage points with ribupatide 4 mg, and −16.3 (95% CI, −18.4 to −14.2) percentage points with ribupatide 6 mg ( P < .001 for all). For at least 5% body weight reduction at week 48, the multiply imputed response rates were 68.1% (95% CI, 59.9% to 75.3%) for ribupatide 2 mg (97 of 142), 88.0% (95% CI, 81.3% to 92.6%) for ribupatide 4 mg (124 of 141), 85.7% (95% CI, 78.6% to 90.7%) with ribupatide 6 mg (121 of 141), and 16.0% (95% CI, 10.8% to 23.1%) with placebo (23 of 143). Placebo-adjusted differences for ribupatide 2, 4, and 6 mg were 52.0 (95% CI, 42.2 to 61.9), 72.0 (95% CI, 63.7 to 80.2), and 69.7 (95% CI, 61.1 to 78.3) percentage points, respectively (all P < .001). The most frequent treatment-emergent adverse events with ribupatide were gastrointestinal events, occurring in 47.9%, 58.2%, and 63.1% of participants receiving ribupatide 2 mg, 4 mg, and 6 mg, respectively, compared with 23.1% receiving placebo; most were mild to moderate in severity and few participants (0.7%) permanently discontinued study treatment because of adverse events. CONCLUSIONS AND RELEVANCE Among adults in China with overweight or obesity without diabetes, once-weekly subcutaneous ribupatide resulted in significantly greater weight loss at 48 weeks. Gastrointestinal adverse events were the most frequent tolerability findings. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT06396429

JAMA
Tongji University (CN), Harbin Medical University (CN), Guangxi Medical University (CN), Jilin University (CN), Fudan University (CN), Zhumadian Central Hospital (CN), Ganzhou People's Hospital (CN), Jiangxi Provincial People's Hospital (CN), Affiliated Hospital of Guizhou Medical University (CN), Gansu Provincial Hospital (CN), Fourth Affiliated Hospital of Harbin Medical University (CN), Zhongshan Hospital (CN), The First People’s Hospital of Lianyungang (CN), The Affiliated Yongchuan Hospital of Chongqing Medical University (CN), Huizhou Central People's Hospital (CN), Peking University Third Hospital (CN), Second Affiliated Hospital of Jilin University (CN), Jiangsu Hengrui Medicine (China) (CN), Shandong First Medical University (CN), Lu'an First People's Hospital (CN), Guangzhou Medical University (CN)
Pharmacology and Obesity Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon